Top accelerator startups

14,448 startups · 29 programs

Keylika

Active · Redefining the Standard of Care for Iron Deficiency Anemia

4signal of 100 · rising 1
  • went through YCProgram · this site+4

A sum of public facts, not a judgement and not investment advice.

Competitors

Adjacent

Also from S22 in AI

All of S22

About Keylika

Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.

YC batch
S22 · Summer 2022
Status, per YC
Active
Category
AI
Team size
1
Location
San Francisco, CA, USA; Walnut Creek, CA, USA
Checked
7h ago

YC tags: AI-powered Drug Discovery, Medical Devices, Drug Delivery, Nanotechnology, Therapeutics

Keylika in S22: 233 companies, 54% AI

Keylika: questions

Which YC batch was Keylika in?

Keylika was in Y Combinator's Summer 2022 batch (S22).

Is Keylika still active?

Y Combinator lists Keylika as active.

Where is Keylika based?

Keylika lists San Francisco, CA, USA; Walnut Creek, CA, USA as its location on YC's directory.